Panitumumab (anti-EGFR) 帕尼单抗 (anti-EGFR)|西域试剂

Panitumumab (anti-EGFR) 帕尼单抗 (anti-EGFR),98.00%

产品编号：Bellancom-P99041A

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99041A		￥1850.00	杭州北京（现货）
Bellancom-P99041A		￥6800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Panitumumab (anti-EGFR) 帕尼单抗 (anti-EGFR)

产品介绍

Panitumumab (anti-EGFR) 是一种全人源 IgG2 抗 EGFR 单克隆抗体，具有抗肿瘤活性。Panitumumab (anti-EGFR) 抑制肿瘤细胞增殖、存活和血管生成。Panitumumab (anti-EGFR) 可用于癌症研究，例如结肠癌。

生物活性

Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer^[4].

体外研究

Panitumumab (2 nM-2 μM, 3 h) (anti-EGFR) inhibits ligand-dependent autophosphorylation in EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells.
Panitumumab (0-200 μg/mL, 48 h) (anti-EGFR) inhibits the proliferation of DLD-1 cells^[4].
Panitumumab (80 μg/mL, 24 h) (anti-EGFR) increase beclin-1 (a marker of autophagy) levels in Caco-2 cells and DLD-1 cells^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells
Concentration:	2, 20, 200, 2000 nM
Incubation Time:	3 h
Result:	Inhibited ligand-induced autophosphorylation of EGFR.

体内研究
(In Vivo)

Panitumumab (25, 100, or 500 μg/mouse, i.p., twice a week) (anti-EGFR) inhibits tumor growth in NCI-H1975 and NCI-H1650 xenografts, compared with control (P < 0.0003).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NCI-H1975 and NCI-H1650 xenografts
Dosage:	25, 100, or 500 μg/mouse
Administration:	Intraperitoneal injection (i.p.), twice a week
Result:	Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation. Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.

体内研究

Panitumumab (25, 100, or 500 μg/mouse, i.p., twice a week) (anti-EGFR) inhibits tumor growth in NCI-H1975 and NCI-H1650 xenografts, compared with control (P < 0.0003).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NCI-H1975 and NCI-H1650 xenografts
Dosage:	25, 100, or 500 μg/mouse
Administration:	Intraperitoneal injection (i.p.), twice a week
Result:	Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation. Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.

体内研究

Panitumumab (25, 100, or 500 μg/mouse, i.p., twice a week) (anti-EGFR) inhibits tumor growth in NCI-H1975 and NCI-H1650 xenografts, compared with control (P < 0.0003).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NCI-H1975 and NCI-H1650 xenografts
Dosage:	25, 100, or 500 μg/mouse
Administration:	Intraperitoneal injection (i.p.), twice a week
Result:	Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation. Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.